Startups
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects. For further information on the company, please visit www.destinypharma.com
Overview
Location
United Kingdom, England, Brighton
Employees
11-50
Total raised
$4.73M
Founded date
1997
Investors 4
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Bioscience Managers | biosciencemanagers.com | |
| Downing Ventures | downing.co.uk | |
| Juno Capital | junocapital.co.uk |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 17, 2021 | Destiny Pharma : Grant of share options | Destiny Pharma plc ("Destiny Pharma" or the "Company") Grant of share options Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage biotechnology company focused on the development of novel medicines t... |
| Nov 15, 2021 | Destiny Pharma : Directorate Change | Destiny Pharma plc ("Destiny Pharma" or "the Company") Directorate change Brighton, United Kingdom - 15 November 2021- Destiny Pharma plc (AIM: DEST) a clinical stage biotechnology company focused on the development of n... |
| Nov 4, 2021 | SAB Member Prof. Gerding is Keynote at C.diff Conf | Destiny Pharma plc ("Destiny Pharma" or "the Company") Destiny Pharma's SAB Member Professor Dale Gerding is Keynote Speaker at C. diff.International Conference Brighton, United Kingdom - 4th November 2021 -Destiny Pharm... |
| Oct 18, 2021 | Destiny Pharma : Study gives strong support for potential of XF-73 | Destiny Pharma plc ("Destiny Pharma" or "the Company") Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potenti... |
| Sep 9, 2021 | Destiny Pharma : Interim results for six months ended 30 June 2021 | Destiny Pharma plc ('Destiny Pharma'or the 'Company') Interim results for the six months ended 30 June 2021 Primary endpoint met in XF-73 Phase 2b clinical trial Secondary endpoint analysis showed XF-73 exhibited a significant and sustained... |
| Jul 9, 2021 | Destiny Pharma : 09 July 2021 – XF-73 Phase 2b data to be presented at ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract Brighton, U... |
| Jun 10, 2021 | DESTINY PHARMA PLC Destiny Pharma : 10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress XF-73 met its primary end point with >99% nasal aureus red... |
| Jun 10, 2021 | DESTINY PHARMA PLC Destiny Pharma : XF-73 data abstract to be presented at 2021 ECCMID | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress · XF-73 met its primary end point with >99% nasal S. aureu... |
| May 19, 2021 | Destiny Pharma : Notice to Register for 2021 AGM | Destiny Pharma plc ('Destiny Pharma' or 'the Company') Notice to Register for 2021 AGM Brighton, United Kingdom - 19 May 2021- Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of no... |
Show more
Reviews 0
FAQ about Destiny Pharma
When was Destiny Pharma founded?
Destiny Pharma was founded in 1997.
How much funding has Destiny Pharma raised?
Destiny Pharma has raised $4.73M in total across 1 funding round.
Who has invested in Destiny Pharma?
Parsers VC lists 4 investors of Destiny Pharma, among them Bioscience Managers, Downing Ventures and Juno Capital.
What has the press written about Destiny Pharma?
Parsers VC has collected 25 articles mentioning Destiny Pharma, among them “Destiny Pharma : Grant of share options” (Dec 17, 2021) and “Destiny Pharma : Directorate Change” (Nov 15, 2021).
Is Destiny Pharma still active?
Yes, Destiny Pharma is active; its latest activity on Parsers VC dates from Jun 17, 2024.